Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Allan M Glanzman

Showing results (51-60 of 71) with videos related to

Pageof 8
Sort By:
Neuromuscular Disorders : NMD|June 8, 2021
Age related treatment effect in type II Spinal Muscular Atrophy pediatric patients treated with nusinersenGiorgia Coratti, Marika Pane, Simona Lucibello, et al.
Neuromuscular Disorders : NMD|January 19, 2016
Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trialsEugenio Mercuri, Richard Finkel, Jacqueline Montes, et al.
Plos One|June 27, 2018
Ambulatory function in spinal muscular atrophy: Age-related patterns of progressionJacqueline Montes, Michael P McDermott, Elizabeth Mirek, et al.
Archives of Neurology|February 16, 2011
Observational study of spinal muscular atrophy type 2 and 3: functional outcomes over 1 yearPetra Kaufmann, Michael P McDermott, Basil T Darras, et al.
Pediatric Physical Therapy : the Official Publication of the Section on Pediatrics of the American Physical Therapy Association|June 21, 2018
Quantitative Evaluation of Lower Extremity Joint Contractures in Spinal Muscular Atrophy: Implications for Motor FunctionRachel Salazar, Jacqueline Montes, Sally Dunaway Young, et al.
Neuromuscular Disorders : NMD|June 27, 2024
Changes in abilities over the initial 12 months of nusinersen treatment for type II SMAGiorgia Coratti, Matthew Civitello, Annemarie Rohwer, et al.
Molecular Genetics and Metabolism|February 11, 2026
A novel patient-Centered approach to clinical trial readiness in rare diseases: Application in Aicardi-Goutières Syndrome (AGS)Anjana Sevagamoorthy, Francesco Gavazzi, Zarrin Tashnim, et al.
Neurology|October 19, 2012
Prospective cohort study of spinal muscular atrophy types 2 and 3Petra Kaufmann, Michael P McDermott, Basil T Darras, et al.
Neuromuscular Disorders : NMD|September 19, 2024
Upper limb function changes over 12 months in untreated SMA II and III individuals: an item-level analysis using the Revised Upper Limb ModuleGiorgia Coratti, Matthew Civitello, Annemarie Rohwer, et al.
Journal of Clinical Medicine|March 11, 2023
2-Year Change in Revised Hammersmith Scale Scores in a Large Cohort of Untreated Paediatric Type 2 and 3 SMA ParticipantsGeorgia Stimpson, Danielle Ramsey, Amy Wolfe, et al.
Pageof 8

Showing results (51-60 of 71) with videos related to

Sort By:
Pageof 8
Neuromuscular Disorders : NMD|June 8, 2021
Age related treatment effect in type II Spinal Muscular Atrophy pediatric patients treated with nusinersenGiorgia Coratti, Marika Pane, Simona Lucibello, et al.
Neuromuscular Disorders : NMD|January 19, 2016
Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trialsEugenio Mercuri, Richard Finkel, Jacqueline Montes, et al.
Plos One|June 27, 2018
Ambulatory function in spinal muscular atrophy: Age-related patterns of progressionJacqueline Montes, Michael P McDermott, Elizabeth Mirek, et al.
Archives of Neurology|February 16, 2011
Observational study of spinal muscular atrophy type 2 and 3: functional outcomes over 1 yearPetra Kaufmann, Michael P McDermott, Basil T Darras, et al.
Pediatric Physical Therapy : the Official Publication of the Section on Pediatrics of the American Physical Therapy Association|June 21, 2018
Quantitative Evaluation of Lower Extremity Joint Contractures in Spinal Muscular Atrophy: Implications for Motor FunctionRachel Salazar, Jacqueline Montes, Sally Dunaway Young, et al.
Neuromuscular Disorders : NMD|June 27, 2024
Changes in abilities over the initial 12 months of nusinersen treatment for type II SMAGiorgia Coratti, Matthew Civitello, Annemarie Rohwer, et al.
Molecular Genetics and Metabolism|February 11, 2026
A novel patient-Centered approach to clinical trial readiness in rare diseases: Application in Aicardi-Goutières Syndrome (AGS)Anjana Sevagamoorthy, Francesco Gavazzi, Zarrin Tashnim, et al.
Neurology|October 19, 2012
Prospective cohort study of spinal muscular atrophy types 2 and 3Petra Kaufmann, Michael P McDermott, Basil T Darras, et al.
Neuromuscular Disorders : NMD|September 19, 2024
Upper limb function changes over 12 months in untreated SMA II and III individuals: an item-level analysis using the Revised Upper Limb ModuleGiorgia Coratti, Matthew Civitello, Annemarie Rohwer, et al.
Journal of Clinical Medicine|March 11, 2023
2-Year Change in Revised Hammersmith Scale Scores in a Large Cohort of Untreated Paediatric Type 2 and 3 SMA ParticipantsGeorgia Stimpson, Danielle Ramsey, Amy Wolfe, et al.
Pageof 8